Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 21 04:00PM ET
33.70
Dollar change
+0.20
Percentage change
0.60
%
Index- P/E17.57 EPS (ttm)1.92 Insider Own22.85% Shs Outstand445.99M Perf Week2.84%
Market Cap19.43B Forward P/E6.42 EPS next Y5.25 Insider Trans0.00% Shs Float334.29M Perf Month1.11%
Income858.77M PEG1.37 EPS next Q1.06 Inst Own74.34% Short Float4.11% Perf Quarter34.16%
Sales2.26B P/S8.58 EPS this Y13.16% Inst Trans1.33% Short Ratio3.38 Perf Half Y19.46%
Book/sh15.58 P/B2.16 EPS next Y12.46% ROA4.96% Short Interest13.75M Perf Year11.66%
Cash/sh1.71 P/C19.68 EPS next 5Y12.82% ROE12.75% 52W Range24.05 - 34.20 Perf YTD32.11%
Dividend Est.0.93 (2.76%) P/FCF6.96 EPS past 5Y-21.51% ROI6.33% 52W High-1.46% Beta0.46
Dividend TTM0.85 (2.52%) Quick Ratio1.44 Sales past 5Y4.79% Gross Margin- 52W Low40.12% ATR (14)0.62
Dividend Ex-DateFeb 21, 2025 Current Ratio1.44 EPS Y/Y TTM-24.34% Oper. Margin57.07% RSI (14)63.75 Volatility1.47% 1.90%
Employees99 Debt/Eq1.10 Sales Y/Y TTM-3.85% Profit Margin37.93% Recom1.44 Target Price41.00
Option/ShortYes / Yes LT Debt/Eq0.95 EPS Q/Q-57.76% Payout43.94% Rel Volume1.73 Prev Close33.50
Sales Surprise7.99% EPS Surprise9.15% Sales Q/Q-0.34% EarningsFeb 11 BMO Avg Volume4.07M Price33.70
SMA201.25% SMA504.97% SMA20019.02% Trades Volume7,065,045 Change0.60%
Date Action Analyst Rating Change Price Target Change
Jun-03-24Downgrade UBS Buy → Neutral $28
Jun-14-22Resumed UBS Buy $47
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Today 11:30AM
05:12AM
Feb-27-25 04:15PM
Feb-23-25 03:03PM
Feb-13-25 07:57PM
09:06AM Loading…
Feb-12-25 09:06AM
06:30AM
02:07AM
Feb-11-25 07:33AM
07:15AM
Feb-10-25 08:03AM
Jan-29-25 09:00AM
Jan-28-25 04:15PM
Jan-23-25 06:29AM
Jan-15-25 01:52PM
11:24AM Loading…
Jan-12-25 11:24AM
Jan-11-25 01:10PM
Jan-10-25 07:30AM
07:15AM
Jan-09-25 04:15PM
Dec-27-24 05:47AM
Dec-24-24 04:45AM
Dec-19-24 08:06PM
Nov-27-24 04:15PM
11:11AM
Nov-14-24 04:30PM
Nov-07-24 07:10AM
02:10AM
12:08AM
Nov-06-24 07:16PM
07:15AM Loading…
07:15AM
Nov-04-24 04:15PM
04:01PM
Nov-03-24 06:11AM
Oct-16-24 04:15PM
Oct-11-24 08:15AM
Oct-09-24 05:31PM
03:50PM
Sep-03-24 05:14PM
05:06PM
Aug-28-24 04:15PM
Aug-26-24 06:16AM
Aug-23-24 05:32AM
Aug-17-24 03:58PM
Aug-16-24 06:09PM
Aug-09-24 01:05AM
Aug-08-24 04:16PM
07:00AM
Jul-24-24 08:30AM
Jul-19-24 08:15AM
Jul-17-24 04:15PM
Jul-15-24 12:10PM
Jul-02-24 07:44PM
06:58PM
Jun-26-24 06:00AM
Jun-24-24 12:56PM
Jun-05-24 06:14AM
Jun-04-24 04:15PM
Jun-03-24 05:15PM
May-28-24 07:10AM
May-27-24 06:28PM
May-25-24 11:10PM
May-22-24 04:10PM
04:00PM
May-20-24 02:41PM
May-13-24 08:15AM
May-10-24 01:07AM
May-09-24 03:35PM
12:00PM
11:56AM
10:46AM
08:10AM
07:00AM
06:45AM
May-08-24 08:51AM
May-06-24 09:16AM
May-02-24 04:01PM
10:01AM
Apr-30-24 08:37AM
Apr-19-24 08:15AM
Apr-17-24 08:15AM
Mar-17-24 08:50AM
Feb-28-24 04:15PM
Feb-20-24 12:45PM
Feb-17-24 12:15AM
Feb-16-24 03:30PM
09:45AM
12:04AM
Feb-15-24 11:08PM
07:58AM
07:30AM
Jan-31-24 01:04AM
Jan-30-24 04:15PM
Jan-19-24 08:15AM
Jan-08-24 07:00AM
Dec-18-23 05:30AM
Nov-27-23 04:15PM
Nov-13-23 08:10AM
08:00AM
Nov-09-23 04:33PM
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.